Our Mission

The Critical Path to TB Drug Regimens (CPTR) initiative aims to speed the development and impact of new and markedly improved drug regimens and rapid drug-susceptibility tests for tuberculosis. Co-founded by the Bill & Melinda Gates Foundation, the Critical Path Institute, and the TB Alliance, CPTR is a collaboration of leading international pharmaceutical and diagnostic companies, public health experts, civil society organizations, and regulatory authorities from around the world. The initiaitve facilitates partnership and collaboration to identify and advance the most promising combinations of new TB drugs and diagnostics, regardless of the sponsor. The initiative also focuses on developing new regulatory pathways and other tools needed to support regimen development—to overcome the obstacles standing in the way of new TB drugs.